

## PRESS RELEASE

### CHROMA STRENGTHENS ITS BOARD THROUGH THE APPOINTMENT OF KLAUS VEITINGER AS NON-EXECUTIVE DIRECTOR

**Oxford, 22 May 2007** – Chroma Therapeutics Limited today announces that it has appointed Klaus Veitinger M.D. as a non-executive director. Dr. Veitinger has over 15 years experience within the pharmaceutical industry and has held senior management positions in drug development, licensing and business development, strategic planning and M&A, as well as general management. Most recently Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma Inc. with responsibility for its US and Asia business. Dr. Veitinger served as a Director of BoneCare International and AnorMED Inc. until their ultimate sale. He served on the Board of Aryx Pharmaceuticals and was a Director of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA) for seven years.

Peter Allen, Chairman of Chroma, commented: “We are delighted that Klaus has decided to join the Board of Chroma. His extensive experience within the pharmaceutical and biotechnology sectors will be invaluable as Chroma continues to rapidly progress its highly innovative product pipeline.”

Dr. Veitinger earned his medical degree at the University of Heidelberg and holds a US medical certification. He earned his doctorate in pathophysiology at the University of Heidelberg and his MBA at INSEAD.

#### Enquiries

##### **Chroma Therapeutics Limited**

Ian Nicholson	Chief Executive Officer	+44 (0)1235 829120
Richard Bungay	Chief Financial Officer	

##### **Brunswick**

Jon Coles		+44 (0)20 7404 5959
Justine McIlroy		



## **PRESS RELEASE**

### **About Chroma Therapeutics**

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at [www.chromatherapeutics.com](http://www.chromatherapeutics.com).